Tasly Pharmaceutical Group Co., Ltd (SHA:600535)

Market Cap	23.43B
Revenue (ttm)	8.50B
Net Income (ttm)	974.68M
Shares Out	1.49B
EPS (ttm)	0.65
PE Ratio	24.03
Forward PE	17.72
Dividend	0.53 (3.38%)
Ex-Dividend Date	Mar 26, 2025

Volume	7,734,427
Average Volume	13,639,818
Open	15.67
Previous Close	15.69
Day's Range	15.64 - 15.78
52-Week Range	12.24 - 17.77
Beta	0.44
RSI	46.25
Earnings Date	Aug 22, 2025

About SHA:600535

Tasly Pharmaceutical Group Co., Ltd engages in the pharmaceutical business in China and internationally. The company provides prescription drugs covering various therapeutic areas, including cardiovascular and cerebrovascular, hepato-biliary-pancreatic, respiratory system, diabetes, tumor immunity, gastrointestinal disease, gynecological, rheumatism, soothe the nerves, pruritus, and andrological areas, as well as over-the-counter drugs. Tasly Pharmaceutical Group Co., Ltd was founded in 1994 and is headquartered in Tianjin, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Employees: 10,958
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600535

Financial Performance

In 2024, SHA:600535's revenue was 8.50 billion, a decrease of -2.03% compared to the previous year's 8.67 billion. Earnings were 955.59 million, a decrease of -10.78%.